Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19

Thomson Reuters ONE May 25, 2020

Algernon Submits for Ethics Approval in Australia for Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

GlobeNewswire May 15, 2020

Algernon Announces Closing of $6.8 Million Private Placement Offering, Including Exercise of the Over-Allotment Option

GlobeNewswire May 13, 2020

Algernon Receives Ethics Approval for Next Phase of Fibrosis & Chronic Cough Treatment Study

Stockhouse Editorial May 6, 2020

Algernon Receives First Ethics Approval for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia

GlobeNewswire May 6, 2020

IIROC Trade Resumption - AGN

Canada NewsWire May 5, 2020

Algernon Amends Terms of Private Placement Offering of Special Warrants

GlobeNewswire May 5, 2020

IIROC Trading Halt - AGN

Canada NewsWire May 5, 2020

IIROC Trade Resumption - AGN

Canada NewsWire May 1, 2020

Algernon Pharmaceuticals Announces up to $5.0 Million Private Placement Offering of Special Warrants

GlobeNewswire April 30, 2020

IIROC Trading Halt - AGN

Canada NewsWire April 30, 2020

IIROC Trade Resumption - AGN

Canada NewsWire April 29, 2020

Algernon Receives Clearance from Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial

GlobeNewswire April 29, 2020

IIROC Trading Halt - AGN

Canada NewsWire April 29, 2020

Algernon Presents "The Science of Ifenprodil" on a Special BioPub Webcast Hosted by Dr. KSS, MD, PhD

GlobeNewswire April 29, 2020

The Top Coronavirus-Related Small-Caps & Bullboards

Stockhouse Editorial April 27, 2020

Algernon Receives Regulatory and Ethics Approval for Phase 2 Ifenprodil COVID-19 Human Study in South Korea

GlobeNewswire April 23, 2020

Algernon Submits Next Phase of COVID Trial to Health Canada

Stockhouse Editorial April 22, 2020

Algernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial

GlobeNewswire April 22, 2020

Acquisition of Common Shares of Algernon Pharmaceuticals Inc.

GlobeNewswire April 20, 2020